ArticleMultiple sclerosis international2011
Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.
Article in Multiple sclerosis international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Serum Neurofilament Light Chain Predicts Stroke Outcome and is a Potential Marker for Treatment Effects of Neural Stem Cell-derived Extracellular Vesicles in a Rat Stroke Model.Translational stroke research · 2026Article
- Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis.Brain communications · 2026Article
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.Biomedicines · 2022Review
- RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis.Cell reports · 2021Article
- Pathomechanisms of Blood-Brain Barrier Disruption in ALS.Neuroscience journal · 2019Review
- Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?International journal of molecular sciences · 2015Review
- Microscale depletion of high abundance proteins in human biofluids using IgY14 immunoaffinity resin: analysis of human plasma and cerebrospinal fluid.Analytical and bioanalytical chemistry · 2014Article
- Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression.Molecular neurobiology · 2013Article
- The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.Multiple sclerosis international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following emerging evidence that neurodegenerative processes in multiple sclerosis (MS) are present from its early stages, an intensive scientific interest has been directed to biomarkers of neuro-axonal damage in body fluids of MS patients. Recent research has introduced new candidate biomarkers but also elucidated pathogenetic and clinical relevance of the well-known ones. This paper reviews the existing data on blood and cerebrospinal fluid biomarkers of neuroaxonal damage in MS and highlights their relation to clinical parameters, as well as their potential predictive value to estimate future disease course, disability, and treatment response. Strategies for future research in this field are suggested.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.